Eteplirsen for the treatment of Duchenne muscular dystrophy
Top Cited Papers
- 10 September 2013
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 74 (5), 637-647
- https://doi.org/10.1002/ana.23982
Abstract
Objective In prior open‐label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51. The present study used a double‐blind placebo‐controlled protocol to test eteplirsen's ability to induce dystrophin production and improve distance walked on the 6‐minute walk test (6MWT). Methods DMD boys aged 7 to 13 years, with confirmed deletions correctable by skipping exon 51 and ability to walk 200 to 400 m on 6 MWT, were randomized to weekly intravenous infusions of 30 or 50 mg/kg/wk eteplirsen or placebo for 24 weeks (n = 4/group). Placebo patients switched to 30 or 50 mg/kg eteplirsen (n = 2/group) at week 25; treatment was open label thereafter. All patients had muscle biopsies at baseline and week 48. Efficacy included dystrophin‐positive fibers and distance walked on the 6MWT. Results At week 24, the 30 mg/kg eteplirsen patients were biopsied, and percentage of dystrophin‐positive fibers was increased to 23% of normal; no increases were detected in placebo‐treated patients (p ≤ 0.002). Even greater increases occurred at week 48 (52% and 43% in the 30 and 50 mg/kg cohorts, respectively), suggesting that dystrophin increases with longer treatment. Restoration of functional dystrophin was confirmed by detection of sarcoglycans and neuronal nitric oxide synthase at the sarcolemma. Ambulation‐evaluable eteplirsen‐treated patients experienced a 67.3 m benefit compared to placebo/delayed patients (p ≤ 0.001). Interpretation Eteplirsen restored dystrophin in the 30 and 50 mg/kg/wk cohorts, and in subsequently treated, placebo‐controlled subjects. Duration, more than dose, accounted for dystrophin production, also resulting in ambulation stability. No severe adverse events were encountered. Ann Neurol 2013;74:637–647Keywords
This publication has 26 references indexed in Scilit:
- Evidence‐based path to newborn screening for duchenne muscular dystrophyAnnals of Neurology, 2012
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Systemic Administration of PRO051 in Duchenne's Muscular DystrophyThe New England Journal of Medicine, 2011
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial managementThe Lancet Neurology, 2010
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsHuman Mutation, 2009
- Local Dystrophin Restoration with Antisense Oligonucleotide PRO051The New England Journal of Medicine, 2007
- Quality of Life, Physical Disability, and Respiratory Impairment in Duchenne Muscular DystrophyAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Dystrophin and mutations: one gene, several proteins, multiple phenotypesThe Lancet Neurology, 2003
- Duchenne Muscular DystrophyAmerican Journal of Physical Medicine & Rehabilitation, 1995